{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:25:06Z","timestamp":1790277906672,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recurrent urinary tract infections (RUTIs) and recurrent vulvovaginal candidiasis (RVVCs) represent major healthcare problems with high socio-economic impact worldwide. Antibiotic and antifungal prophylaxis remain the gold standard treatments for RUTIs and RVVCs, contributing to the massive rise of antimicrobial resistance, microbiota alterations and co-infections. Therefore, the development of novel vaccine strategies for these infections are sorely needed. The sublingual heat-inactivated polyvalent bacterial vaccine MV140 shows clinical efficacy for the prevention of RUTIs and promotes Th1\/Th17 and IL-10 immune responses. V132 is a sublingual preparation of heat-inactivated <jats:italic>Candida albicans<\/jats:italic> developed against RVVCs. A vaccine formulation combining both MV140 and V132 might well represent a suitable approach for concomitant genitourinary tract infections (GUTIs), but detailed mechanistic preclinical studies are still needed. Herein, we showed that the combination of MV140 and V132 imprints human dendritic cells (DCs) with the capacity to polarize potent IFN-\u03b3\u2013 and IL-17A\u2013producing T cells and FOXP3<jats:sup>+<\/jats:sup> regulatory T (Treg) cells. MV140\/V132 activates mitogen-activated protein kinases (MAPK)-, nuclear factor-\u03baB (NF-\u03baB)- and mammalian target of rapamycin (mTOR)-mediated signaling pathways in human DCs. MV140\/V132 also promotes metabolic and epigenetic reprogramming in human DCs, which are key molecular mechanisms involved in the induction of innate trained immunity. Splenocytes from mice sublingually immunized with MV140\/V132 display enhanced proliferative responses of CD4<jats:sup>+<\/jats:sup> T cells not only upon <jats:italic>in vitro<\/jats:italic> stimulation with the related antigens contained in the vaccine formulation but also upon stimulation with phytohaemagglutinin. Additionally, <jats:italic>in vivo<\/jats:italic> sublingual immunization with MV140\/V132 induces the generation of IgG and IgA antibodies against all the components contained in the vaccine formulation. We uncover immunological mechanisms underlying the potential mode of action of a combination of MV140 and V132 as a novel promising trained immunity-based vaccine (TIbV) for GUTIs.<\/jats:p>","DOI":"10.3389\/fimmu.2020.612269","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T06:12:34Z","timestamp":1611209554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections"],"prefix":"10.3389","volume":"11","author":[{"given":"Leticia","family":"Martin-Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Sevilla-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Benito-Villalvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen M.","family":"Diez\u2010Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sanchez-Ram\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Subiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0324-0","article-title":"Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies","volume":"18","author":"Klein","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther Adv Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.11214","article-title":"Guidelines for the diagnosis and management of recurrent urinary tract infection in women","volume":"5","author":"Dason","year":"2011","journal-title":"Can Urol Assoc J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30003-7","article-title":"The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later","volume":"20","author":"Laxminarayan","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3402\/mehd.v26.27799","article-title":"Changes in vaginal microbiota following antimicrobial and probiotic therapy","volume":"26","author":"Macklaim","year":"2015","journal-title":"Microb Ecol Health Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2015.1091805","article-title":"Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors","volume":"42","author":"Goncalves","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11908-019-0700-y","article-title":"Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure","volume":"21","author":"Shukla","year":"2019","journal-title":"Curr Infect Dis Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2008.04.070169","article-title":"Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study","volume":"21","author":"Xu","year":"2008","journal-title":"J Am Board Fam Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/493508","article-title":"Tetracycline effects on Candida albicans virulence factors","volume":"2008","author":"McCool","year":"2008","journal-title":"Infect Dis Obstet Gynecol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326080-00005","article-title":"Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England","volume":"26","author":"Wilton","year":"2003","journal-title":"Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60917-9","article-title":"Vulvovaginal candidosis","volume":"369","author":"Sobel","year":"2007","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajog.2015.06.067","article-title":"Recurrent vulvovaginal candidiasis","volume":"214","author":"Sobel","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/13693786.2010.497972","article-title":"Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species","volume":"49","author":"Guzel","year":"2011","journal-title":"Med Mycol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12905-019-0748-8","article-title":"Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes","volume":"19","author":"Yano","year":"2019","journal-title":"BMC Womens Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000413","article-title":"Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy","volume":"22","author":"Crouss","year":"2018","journal-title":"J Low Genit Tract Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1359543","article-title":"Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT)","volume":"18","author":"Wagenlehner","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05228-3","article-title":"Influence of recurrent vulvovaginal candidiasis on quality of life issues","volume":"300","author":"Fukazawa","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01509","article-title":"Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections","volume":"11","author":"Loubet","year":"2020","journal-title":"Front Microbiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02936","article-title":"Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations","volume":"9","author":"Sanchez-Ramon","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666160829143129","article-title":"New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice","volume":"22","author":"Tejera-Alhambra","year":"2016","journal-title":"Curr Pharm Des"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00897","article-title":"The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future","volume":"9","author":"Tso","year":"2018","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.112","article-title":"MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88","volume":"10","author":"Benito-Villalvilla","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201747024","article-title":"Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways","volume":"48","author":"Cirauqui","year":"2018","journal-title":"Eur J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":":203","DOI":"10.3390\/biomedicines8070203","article-title":"Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study","volume":"8","author":"Guevara-Hoyer","year":"2020","journal-title":"Biomedicines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.04.006","article-title":"Trained immunity: a memory for innate host defense","volume":"9","author":"Netea","year":"2011","journal-title":"Cell Host Microbe"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2012.06.006","article-title":"Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes","volume":"12","author":"Quintin","year":"2012","journal-title":"Cell Host Microbe"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1250684","article-title":"mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity","volume":"345","author":"Cheng","year":"2014","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251086","article-title":"Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity","volume":"345","author":"Saeed","year":"2014","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.089","article-title":"The mucosal immune system for vaccine development","volume":"32","author":"Lamichhane","year":"2014","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12555","article-title":"Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells","volume":"278","author":"Palomares","year":"2017","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00775","article-title":"Metabolic Control of Dendritic Cell Functions: Digesting Information","volume":"10","author":"Wculek","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.70","article-title":"Rathmell J. A guide to immunometabolism for immunologists","volume":"16","author":"O\u2019Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/all.14036","article-title":"Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs","volume":"75","author":"Benito-Villalvilla","year":"2020","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6690","article-title":"Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future","volume":"14","author":"Nickel","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-012-1853-5","article-title":"Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics","volume":"24","author":"Lorenzo-Gomez","year":"2013","journal-title":"Int Urogynecol J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2015.00050","article-title":"Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections","volume":"5","author":"Lorenzo-Gomez","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14067","article-title":"First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune((R))","volume":"121","author":"Yang","year":"2018","journal-title":"BJU Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12879-019-4541-y","article-title":"Active immunoprophyilaxis with uromune(R) decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects","volume":"19","author":"Ramirez Sevilla","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000505162","article-title":"Analysis of the Efficacy of a Sublingual Bacterial Vaccine in the Prophylaxis of Recurrent Urinary Tract Infection","volume":"104","author":"Carrion-Lopez","year":"2020","journal-title":"Urol Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrmicro1815","article-title":"An integrated model of the recognition of Candida albicans by the innate immune system","volume":"6","author":"Netea","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303316","article-title":"High mitochondrial respiration and glycolytic capacity represent a metabolic phenotype of human tolerogenic dendritic cells","volume":"194","author":"Malinarich","year":"2015","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy185","article-title":"A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial","volume":"66","author":"Edwards","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.069","article-title":"A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models","volume":"30","author":"De Bernardis","year":"2012","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20050749","article-title":"A novel glyco-conjugate vaccine against fungal pathogens","volume":"202","author":"Torosantucci","year":"2005","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.2.826-833.1999","article-title":"Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis","volume":"67","author":"Cardenas-Freytag","year":"1999","journal-title":"Infect Immun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.18","article-title":"Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease","volume":"16","author":"DuPage","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2014.45","article-title":"Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-beta","volume":"15","author":"Palomares","year":"2014","journal-title":"Genes Immun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.19","article-title":"Regulatory T cells are essential to promote proper CD4 T-cell priming upon mucosal infection","volume":"9","author":"Soerens","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00426","article-title":"Microbiome Dependent Regulation of Tregs and Th17 Cells in Mucosa","volume":"10","author":"Pandiyan","year":"2019","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.1601775","article-title":"Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems","volume":"199","author":"Boyaka","year":"2017","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1084\/jem.20151570","article-title":"Immunometabolism governs dendritic cell and macrophage function","volume":"213","author":"O\u2019Neill","year":"2016","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.01.013","article-title":"Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways","volume":"10","author":"Ferreira","year":"2015","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2015.08.036","article-title":"Hypoxia-inducible factor 1alpha modulates metabolic activity and cytokine release in anti-Aspergillus fumigatus immune responses initiated by human dendritic cells","volume":"305","author":"Fliesser","year":"2015","journal-title":"Int J Med Microbiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.08.009","article-title":"mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function","volume":"37","author":"Sukhbaatar","year":"2016","journal-title":"Trends Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00688-13","article-title":"Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors","volume":"21","author":"Ifrim","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4697","article-title":"Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function","volume":"180","author":"Jantsch","year":"2008","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.09.002","article-title":"Immunometabolic circuits in trained immunity","volume":"28","author":"Arts","year":"2016","journal-title":"Semin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/1471-2164-11-642","article-title":"Genome-wide promoter analysis of histone modifications in human monocyte-derived antigen presenting cells","volume":"11","author":"Tserel","year":"2010","journal-title":"BMC Genomics"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0025-4","article-title":"Therapeutic targeting of trained immunity","volume":"18","author":"Mulder","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612269\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T06:12:36Z","timestamp":1611209556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612269\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2020.612269"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.612269","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"article-number":"612269"}}